In May 2023, the U.S. Food and Drug Administration approved a biomarker screening test (sFlt-1/PIGF) at 24–34 weeks of gestation, shown to have a 94% sensitivity and 75% specificity, to identify patients at high risk of severe preeclampsia. The gene discussed is PIGF; the disease is preeclampsia.